- Home
- GBDC vs ZLAB Comparison
GBDC vs ZLAB Comparison
Compare GBDC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBDC
- ZLAB
- Stock Information
- Founded
- GBDC 2009
- ZLAB 2013
- Country
- GBDC United States
- ZLAB China
- Employees
- GBDC N/A
- ZLAB N/A
- Industry
- GBDC Finance: Consumer Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GBDC Finance
- ZLAB Health Care
- Exchange
- GBDC Nasdaq
- ZLAB Nasdaq
- Market Cap
- GBDC 4.0B
- ZLAB 3.6B
- IPO Year
- GBDC 2010
- ZLAB 2017
- Fundamental
- Price
- GBDC $15.36
- ZLAB $37.17
- Analyst Decision
- GBDC Buy
- ZLAB Buy
- Analyst Count
- GBDC 4
- ZLAB 5
- Target Price
- GBDC $15.50
- ZLAB $54.28
- AVG Volume (30 Days)
- GBDC 1.3M
- ZLAB 746.2K
- Earning Date
- GBDC 08-04-2025
- ZLAB 08-07-2025
- Dividend Yield
- GBDC 10.16%
- ZLAB N/A
- EPS Growth
- GBDC N/A
- ZLAB N/A
- EPS
- GBDC 1.18
- ZLAB N/A
- Revenue
- GBDC $830,269,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- GBDC $21.93
- ZLAB $44.07
- Revenue Next Year
- GBDC N/A
- ZLAB $49.13
- P/E Ratio
- GBDC $12.97
- ZLAB N/A
- Revenue Growth
- GBDC 28.08
- ZLAB 43.72
- 52 Week Low
- GBDC $12.68
- ZLAB $16.01
- 52 Week High
- GBDC $16.01
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- GBDC 58.59
- ZLAB 55.44
- Support Level
- GBDC $15.04
- ZLAB $33.55
- Resistance Level
- GBDC $15.55
- ZLAB $37.98
- Average True Range (ATR)
- GBDC 0.21
- ZLAB 1.12
- MACD
- GBDC 0.03
- ZLAB 0.26
- Stochastic Oscillator
- GBDC 68.24
- ZLAB 75.25
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.